Hand Dermatitis Clinical Trials

A listing of Hand Dermatitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 31 clinical trials
Featured trial
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 (TRuE-CHE1)

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).

  • 0 views
  • 15 Jun, 2022
  • 2 locations
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) (ADjoin)

This 110-week study is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis.

hormonal contraception
progestogen
eczema
topical agents
lebrikizumab
  • 608 views
  • 29 Jul, 2022
  • 260 locations
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 (TRuE-CHE1)

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).

  • 0 views
  • 15 Jun, 2022
  • 2 locations
Efficacy of Fecal Microbial Transplantation Treatment in Adults With Atopic Dermatitis

Prospective double-blinded placebo-controlled study, among adult patients suffering from moderate-to-severe atopic dermatitis (AD), insufficiently responsive to topical and systemic treatment. In the first group all patients will receive 4 fecal microbial transplantations (FMTs) from healthy donors each 2 weeks apart. In the second group all patients will receive 4 placebo …

topical agents
atopy
corticosteroids
topical corticosteroid
  • 32 views
  • 12 Aug, 2022
  • 2 locations
Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis

This is a phase II, double blind study with ZEP-3NA 0.1% or 1% vs. vehicle-control in subjects with mild to moderate Atopic Dermatitis. The IP (Investigational Product) will be administered topically twice daily for 4 weeks in the double blind phase. patients that will reach the primary endpoint will have …

atopy
hysterectomy
tubal ligation
  • 8 views
  • 19 Apr, 2022
  • 6 locations
A Phase I/IIa Study to Investigate the GM-XANTHO in Healthy Volunteers and Atopic Dermatitis Patients

A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GM-XANTHO in Healthy Volunteers and to Investigate its Efficacy and Safety Profile in Atopic Dermatitis Patients

blood test
hysterectomy
platelet count
body mass index
Accepts healthy volunteers
  • 49 views
  • 27 Apr, 2022
  • 1 location
A First-in-Human PoC Study With BEN2293 in Patients With Mild to Moderate Atopic Dermatitis

A randomised, adaptive design, double-blind, placebo-controlled, first-in-human, two-part study to investigate the safety, tolerability, PK and preliminary efficacy of multiple topical doses of BEN2293 in patients with mild to moderate AD.

  • 0 views
  • 26 Apr, 2022
  • 1 location
A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis

The purpose of this study is to evaluate the effect of nemolizumab (CD14152) on the pharmacokinetics (PK) of a drug "cocktail" representative of CYP450 (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 sensitive index substrates) in adult participants with moderateto- severe atopic dermatitis (AD).

calcineurin inhibitor
nemolizumab
eczema
topical agents
topical corticosteroid
  • 0 views
  • 10 May, 2022
  • 6 locations
The Role of IL-22/IL-22BP Axis in Atopic Dermatitis (DA/IL-22BP)

Interleukin 22 (IL-22) is known to be regulated by IL-22 binding protein (IL-22BP), a soluble, inhibitory receptor. The potential role of IL-22BP in atopic dermatitis (AD) is mostly unknown and deserves further investigation. The main objective of this study is to better understand the potential protective role of IL-22BP through …

  • 0 views
  • 04 Jul, 2022
  • 1 location
Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis

This is the first time PF-07242813 will be given to humans. The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07242813 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess …

corticosteroids
eczema
asthma
topical agents
Accepts healthy volunteers
  • 0 views
  • 08 Jul, 2022
  • 5 locations